Zynex Inc. (OTCMKTS:ZYXI) – Analysts at Seethru Equity increased their FY2018 earnings per share (EPS) estimates for Zynex in a research note issued on Tuesday. Seethru Equity analyst A. Tandon now forecasts that the company will earn $0.28 per share for the year, up from their prior estimate of $0.16.

Get Zynex Inc. alerts:

Zynex (OTCMKTS:ZYXI) last released its quarterly earnings data on Monday, November 13th. The company reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. The company had revenue of $6.82 million during the quarter, compared to the consensus estimate of $5.52 million. Zynex had a net margin of 24.10% and a negative return on equity of 248.78%.

Other analysts also recently issued research reports about the stock. Taglich Brothers reiterated a “speculative buy” rating on shares of Zynex in a report on Monday, August 21st. Zacks Investment Research upgraded shares of Zynex from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Thursday, November 23rd. Finally, ValuEngine upgraded shares of Zynex from a “hold” rating to a “buy” rating in a report on Wednesday, August 23rd.

Zynex (OTCMKTS:ZYXI) traded down $0.25 during mid-day trading on Friday, reaching $2.48. 72,319 shares of the company’s stock were exchanged, compared to its average volume of 34,518. The firm has a market cap of $98.17, a P/E ratio of 23.00 and a beta of -0.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.19 and a current ratio of 1.27. Zynex has a 12 month low of $0.25 and a 12 month high of $3.25.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/zynex-inc-to-post-fy2018-earnings-of-0-28-per-share-seethru-equity-forecasts-zyxi.html.

Zynex Company Profile

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.